維亞生物(01873.HK)擬配股淨籌10.51億港元 主要用於投資及收購下游業務 午後復牌
格隆匯7月3日丨維亞生物(01873.HK)宣佈,於2020年7月3日,公司與配售代理訂立配售協議,公司擬透過配售代理向不少於6名承配人配售合共1.3億股配售股份,佔公司現有已發行股本的7.71%,及佔經擴大後股本的7.16%;配售價每股8.15港元,較7月2日收市價9.04港元折讓約9.85%。
配售所得款項總額將約為10.60億港元,所得款項淨額估計約為10.51億港元。配售所得款項淨額的約70%用於業務發展及擴張,主要用於投資及收購下游業務(包括小分子合同製造組織、大分子合同製造組織及其他補充業務);及剩餘款項用於營運資金及一般企業用途。
此外,公司股份將自下午1時正起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.